Home
ExcellGene

ExcellGene Market Share Analysis for June 2026

Discover cutting-edge CHO and HEK293 manufacturing solutions. Accelerate and de-risk recombinant biologic drug development with our high-yield, fast, and scalable production technologies.

Science and Education > Biology

Domainexcellgene.com

Year Founded2001

Employees51 - 200

Annual Revenue$2M - $5M

ExcellGene

ExcellGene (including company regionals)

excellgene.com

See more website traffic and engagement information

ExcellGene Revenue up to June 2026 is 2M - 5M

revenue generated by ExcellGene top domains

ExcellGene top domains revenue over 3 years

Revenue for ExcellGene top domains

excellgene.com2M - 5M

See more with Sales Intelligence

Total visits to ExcellGene's top domains

Understand ExcellGene market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

excellgene.com969

See more with Sales Intelligence

Avg. visit duration in ExcellGene's top domains

Analyze ExcellGene engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

excellgene.com00:01:20

See more with Sales Intelligence

Avg. pageviews on ExcellGene's top domains

See how ExcellGene keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

excellgene.com3.05

See more with Sales Intelligence

ExcellGene top competitors by domain

Top similar sites in June 2026, ranked by their affinity

dna20.comCompany NameDNA2.0Employees51 - 200HQUnited States, California, Menlo ParkAnnual revenue--Total visits272Science and Education > Biology

Top technologies used by ExcellGene

These are the website technologies, by industry, used by ExcellGene top domains

Widget (8)

Twemoji

Advertising (3)

DoubleClick

Audio Video Media (2)

Vimeo

Content Management System (2)

WordPress

More Technologies

7

See all

News & Signals from ExcellGene

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsExcellgene SA partnered with Cytovance® Biologics, Inc. on May 8th '24.OKLAHOMA CITY, Oklahoma, MONTHEY, Switzerland, May 8, 2024 - ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.

NewsLottebiologics partners with Excellgene SA.“Through this meaningful agreement with EXCELLGENE, which has experience in projects with leading global biopharmaceutical companies, Lottebiologics will bolster its competitive bidding capabilities of CDMO”

NewsExcellgene SA is developing variant-proof SARS-CoV-2 vaccine on Jan 4th '22.Bharat Biotech also announced last year that along with Switzerland’s ExcellGene SA and University of Sydney it was going to develop a variant-proof SARS-CoV-2 vaccine that was being funded through CEPI (the Coalition for Epidemic Preparedness Innovations).